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Highlights 
z We aimed to identify prognostic plasma proteins associated with onset of chronic GVHD. 
z High-throughput mass spectrometry was used to screen pooled plasma samples. 
z Enzyme-linked immunosorbent assays were used to test individual samples. 
z Higher CD163 concentrations at day 80 were associated with de novo-onset chronic GVHD. 
z Monocyte or macrophage activation may contribute to the pathogenesis of chronic GVHD. 
Abstract 
Chronic graft-versus-host disease (cGVHD) is the leading cause of long-term morbidity and 
mortality after allogeneic hematopoietic cell transplantation. In order to identify prognostic 
plasma proteins associated with de novo or quiescent-onset cGVHD, we performed a discovery 
and validation proteomic study. The total study cohort included 167 consecutive patients who 
had no clinical evidence of GVHD under minimum glucocorticoid administration, and had 
available plasma samples obtained at 80±14 days after transplantation. We first used high-
throughput mass spectrometry to screen pooled plasma using 20 cases with subsequent 
cGVHD and 20 controls without it, and identified 20 candidate proteins. We then measured 12 
of the 20 candidates by enzyme-linked immunosorbent assays on the same individual samples 
and identified 4 proteins for further verification (LGALS3BP, CD5L, CD163 and TXN for de novo 
onset, and LGALS3BP and CD5L for quiescent onset). The verification cohort included 127 
remaining patients. The cumulative incidence of de novo-onset cGVHD was higher in patients 
with higher plasma soluble CD163 concentrations at day 80 than those with lower 
concentrations (75% versus 40%, P=0.018). The cumulative incidence of de novo or quiescent-
onset cGVHD did not differ statistically according to concentrations of the three other proteins at 
day 80. CD163 is a macrophage scavenger receptor and is elevated in oxidative conditions. 
These results suggest that monocyte or macrophage activation or increased oxidative stress 
may contribute to the pathogenesis of cGVHD. 
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Introduction 
Chronic graft-versus-host disease (cGVHD) occurs in approximately 30-50% of patients after 
allogeneic hematopoietic cell transplantation (HCT) and is the leading cause of late morbidity 
and mortality.1 The disease usually occurs beyond 80 days after HCT, and the median onset is 
5 months after HCT.2 This complication is thought to occur because the donor immune system 
recognizes recipient tissues, causing inflammation and fibrosis.3, 4  
High-throughput mass spectrometry is a powerful, comprehensive and reduced-bias 
approach to identify proteomic profiles in many diseases.5 This approach has been very 
successful in identifying plasma biomarker proteins that correlate with activity and treatment 
response of acute GVHD6-11 and diagnosis and severity of chronic GVHD.12, 13 To date, 
prognostic plasma biomarker proteins associated with subsequent onset of chronic GVHD have 
not been examined by mass spectrometry. Furthermore, few studies have considered the 
influence of glucocorticoid dosing when the sample was obtained, despite the large influence of 
glucocorticoids on gene expression and the concentrations of plasma proteins.12, 14 We 
hypothesized that comparing plasma proteomic profiles before the onset of chronic GVHD 
between patients with and without subsequent chronic GVHD could identify prognostic proteins 
associated with the development of chronic GVHD.   
Methods 
Study design 
In order to identify prognostic plasma proteins associated with the subsequent de novo or 
quiescent-onset cGVHD, we performed a discovery and validation proteomic study using high-
throughput mass spectrometry. The study was carried out in 3 phases: (i) an initial discovery 
phase testing pooled plasma samples by mass spectrometry; (ii) confirmation of the candidate 
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proteins in individual samples of the discovery cohort by using enzyme-linked immunosorbent 
assays (ELISA); and (iii) verification of candidate proteins in the remaining patients. 
Patients and sample collection 
Patients gave written consent allowing blood sample collection and the use of medical records 
for research in accordance with the Declaration of Helsinki. The institutional review board of the 
Fred Hutchinson Cancer Research Center approved the study. Patients were recruited before 
transplantation, and blood samples were prospectively collected and cryopreserved at 80±14 
days after transplantation. Plasma was collected in EDTA and aliquoted in 0.5mL tubes and 
stored at -80°C within 2 hours of phlebotomy. Acute GVHD was diagnosed and graded 
according to the previously described criteria.15, 16 Chronic GVHD was diagnosed by the 
National Institutes of Health consensus criteria.17  
The total study cohort included 167 consecutive relapse-free patients who met all of the 
following criteria: (1) allogeneic hematopoietic cell transplantation (HCT) at the Fred Hutchinson 
Cancer Research Center/Seattle Cancer Care Alliance between April 2003 and December 
2011, (2) available plasma samples at day 80±14 days after HCT, (3) no prior cGVHD at the 
time of sample collection, (4) no active GVHD at the time of sample collection, and (5) 
prednisone-equivalent steroid doses ≤5 mg daily at sample collection. Patients were eligible 
regardless of the indication for HCT, conditioning regimen, graft source, donor relationship and 
HLA-matching between the donor and recipient. 
Discovery and verification cohorts 
Patients who subsequently developed systemically treated cGVHD were declared cases, while 
patients without subsequent cGVHD were declared controls. The discovery cohort included two 
pools from 40 patients selected from the 167 patients described above: one pool of 20 patients 
with prior acute GVHD and another pool of 20 without prior acute GVHD. Two independent 
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intact protein analyses (IPA) were done with pooled plasma samples according to presence or 
absence of prior acute GVHD. Among 20 patients with no prior acute GVHD (IPA1), 10 patients 
were cases and 10 were controls. Likewise, among 20 patients with prior acute GVHD (IPA2), 
10 were cases and 10 were controls. Cases and controls were matched for recipient gender 
(Table 1). The verification cohort included the 127 remaining patients. 
Mass spectrometric analysis 
Samples were depleted of the 6 most abundant proteins (albumin, IgG, IgA, transferrin, 
haptoglobin and antitrypsin), pooled and labeled with light acrylamide (cases: subsequent 
cGVHD-positive) or with a heavy 1,2,3-13C-acrylamide (controls: subsequent cGVHD-
negative).5, 18 The pool of cases and the pool of controls were mixed together before further 
processing and IPA analysis. Proteins were separated by an automated online 2D-HPLC 
system controlled by Workstation Class-VP 7.4 (Shimadzu Corporation).5, 18 Separation 
consisted of anion exchange chromatography followed by reverse-phase chromatography. In-
solution tryptic digestion was conducted with lyophilized aliquots from the reverse-phase 
(second dimension) fractionation step.13, 23 Aliquots were subjected to tandem mass 
spectrometry shotgun analysis using an LTQ-Orbitrap (Thermo) mass spectrometer coupled 
with a NanoLC-1D (Eksigent) on a 2-hour gradient.13, 23 
Data processing 
Raw machine output files from all mass spectrometry runs were converted to mzXML files and 
searched with X!Tandem19 configured with the k-score scoring algorithm20 against the Uniprot 
database. Peptide identifications were assigned probability by PeptideProphet,21 with a model 
built on all sample fractions together. As a conservative quality filter, only those identifications 
with an individual identification probability of 0.95 or higher were retained. The Q3 algorithm for 
labeled quantitation22 was applied to estimate quantitative ratios for all cysteine-containing 
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peptides, with a correction for the overlap between light and heavy isotopic peaks. The Qurate 
algorithm23 within the msInspect platform24 was applied in an automated fashion to locate and 
remove peptide quantitative events likely to be incorrect due to apparent coeluting peptides, 
poor isotopic peak distribution, or missing isotopic peaks. 
The remaining peptide identifications were provided to ProteinProphet25 for protein 
inference. Since only high-quality peptide identifications were used, protein probability 
assignments were ignored, except to exclude proteins whose evidence was superseded by 
another protein that explained more of the available peptide evidence. Peptide quantitative 
ratios assigned by Q3 were combined for each protein, and protein ratios were calculated using 
the geometric mean of all remaining retained quantitative ratios. 
For proteins determined to be of interest due to extreme protein-level quantitative ratios, 
Qurate was used again, in a manual analysis mode. Peptide quantitative events for these 
proteins were evaluated on an individual basis, without respect to which protein they 
represented, and events that visually appeared questionable or incorrect were removed from 
the analysis. Proteins were selected for further evaluation only if they were supported by 
quantitative events that passed both automated and manual inspection. The 6 depleted proteins 
and hemoglobin were excluded from candidate proteins.   
ELISA 
Antibody pairs were purchased as follows: IgM (GENWAY, San Diego, CA), lectin galactoside-
binding soluble 3 binding protein (eBioScience, San Diego, CA), gastric inhibitory polypeptide 
(Millipore, Billerica, MA), CD5 molecule-like (CircuLex, Nagano, Japan), latent transforming 
growth factor beta binding protein 2 and haptoglobin-related protein (USCN Life Science, Hubei, 
China), CD163 (R&D Systems, Minneapolis, MN), cartilage acidic protein 1 and PDZ and LIM 
domain 1 (My BioSource, San Diego, CA), trefoil factor 2 (BioVendor, Asheville, NC), 
thioredoxin (Immuno-Biological Laboratories, Gunma, Japan), and heat shock protein 90kDa 
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beta (Grp94), member 1 (Abcam, Cambridge, MA). ELISA assays were performed according to 
manufacturer’s protocols. 
Statistical analysis 
The receiver operating characteristic area under curve was estimated nonparametrically. The 
cumulative incidence of cGVHD was calculated from the date of sample draw at day 80, treating 
death, relapse and late acute GVHD as competing risks, and groups were compared using 
Gray’s test. Protein concentrations between groups were compared using Wilcoxon two-sample 
tests. Two-sided P values <0.05 were considered statistically significant. 
Results 
Discovery phase 
Two independent intact protein analyses were done with pooled plasma samples according to 
presence or absence of prior acute GVHD. IPA1 represents a comparison of cases and controls 
associated with subsequent de novo-onset cGVHD, and IPA2 represents a comparison 
associated with subsequent quiescent-onset cGVHD. Four hundred twenty-two proteins had 
quantitative ratios in both IPA1 and IPA2. Among them, 20 candidate biomarker proteins met 
either of the following criteria (Table 2): (1) concentrations were at least 1.5-fold higher or 0.66-
fold lower in pooled cases compared with pooled controls in both IPA1 and IPA2 (10 proteins), 
or (2) concentrations were at least 1.5-fold higher or 0.66-fold lower in IPA1 but not in IPA2 (10 
proteins). The second criterion was included because persistence of protein alterations 
associated with acute GVHD could mask the identification of protein alterations also associated 
with cGVHD.  
Based on availability of suitable antibodies pair for ELISA measurement, 12 of the 20 
identified proteins were selected for further testing in each discovery sample by ELISA (Table 
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2). Concentrations of these 12 proteins were measured in 38 of the 40 individual plasma 
samples that were used for the IPA1 and IPA2 pools. Two samples (1 case in IPA1 and 1 
control in IPA2) had no left over material after IPA and were not tested by ELISA. Four proteins 
from IPA1 (LGALS3BP, CD5L, CD163 and TXN) and 2 proteins from IPA2 (LGALS3BP and 
CD5L) met the criteria for further verification (ELISA ratio consistent with mass spectrometry 
ratio AND area under the curve ≥0.6) (Table 3).  
Verification phase
We then tested individual plasma samples of the 127 remaining patients who met the same 
eligibility criteria at day 80. Among 62 patients without prior acute GVHD, 41 (66%) developed 
de novo-onset cGVHD. The NIH global severity was mild in 4 patients (10%), moderate in 23 
(56%) and severe in 14 (34%), and 33 (80%) had overlap syndrome. Among 65 patients with 
prior acute GVHD, 41 (63%) developed quiescent-onset cGVHD. The NIH global severity was 
mild in 1 patients (2%), moderate in 22 (54%) and severe in 18 (44%), and 37 (90%) had 
overlap syndrome. Other patient characteristics are summarized in Table 1. The cumulative 
incidence of subsequent cGVHD was compared according to protein concentrations at day 80, 
using the median concentration in the discovery cohort as the threshold (Figure 1). Among the 
candidate proteins, the cumulative incidence of subsequent de novo-onset cGVHD was higher 
in patients with higher plasma soluble CD163 concentrations at day 80 than those with lower 
concentrations (75% versus 40%, P=0.018). The cumulative incidence of subsequent 
quiescent-onset cGVHD did not differ statistically according to LGALS3BP or CD5L 
concentrations. 
Comparison of CD163 concentrations among patients without prior acute GVHD at day 
80 with healthy individuals and with patients with active chronic GVHD 
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We compared CD163 concentration among 81 combined patients without prior acute GVHD at 
day 80 with healthy individuals and with patients with active cGVHD at any time (Figure 2). 
CD163 concentrations were higher among patients with no subsequent cGVHD compared to 
healthy individuals (P=0.038), among patients with subsequent de novo-onset cGVHD 
compared to those with no subsequent cGVHD (P=0.039), and among patients with active 
cGVHD compared to those with subsequent de novo-onset cGVHD (P=0.0049). 
Discussion 
In order to elucidate day 80 plasma protein profiles associated with subsequent onset of cGVHD, 
we used the comprehensive, reduced-bias technology of high-throughput mass spectrometry. 
Discovery analysis identified 20 candidate proteins. Verification analysis was carried out for 12 
of these candidate proteins for which ELISA were available. Measurement of individual samples 
by ELISA showed that 4 of the 12 proteins held promise for further verification. Testing of 
independent samples by ELISA showed that higher plasma soluble CD163 concentrations at 
day 80 were associated with the subsequent de novo-onset cGVHD. 
Our results suggest that monocyte/macrophage activation may contribute to the subsequent 
development of cGVHD. CD163 is a member of the cysteine-rich scavenger receptor 
superfamily and is expressed in monocytes and macrophages that have an anti-inflammatory 
function.26  IL-6 and anti-inflammatory cytokines such as IL-10 increase CD163 expression in 
monocytes and macrophages, while pro-inflammatory mediators such as lipopolysaccharide, 
interferon-γ, and tumor necrosis factor-α suppress CD163 expression.27 Classically activated 
macrophages demonstrate proinflammatory functions, while alternatively activated 
macrophages demonstrate anti-inflammatory functions, regulate tissue repair and remodeling,28-
30 mediate cGVHD in murine models,31 and accumulate in fibrotic lesions in both mice and 
patients with cGVHD.31-33 Taken together, increased concentrations of plasma CD163 could 
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reflect increased alternatively-activated monocytes and macrophages that are pathogenic for 
cGVHD. 
Although CD163 concentrations at day 80 after transplantation were associated with the 
subsequent development of de novo-onset cGVHD, CD163 was not a candidate for quiescent-
onset cGVHD in mass spectrometry analysis. CD163-positive macrophages in the skin and 
bone marrow have been associated with refractory acute GVHD and poor prognosis.34, 35 Thus 
CD163 concentrations might have been strongly influenced by the prior onset of acute GVHD 
and its treatment, and could have obscured any association with subsequent quiescent-onset 
cGVHD. 
CD163 also functions as an acute phase-regulated receptor involved in the clearance and 
endocytosis of hemoglobin-haptoglobin complexes by macrophages,36 thereby protecting 
tissues from free hemoglobin-mediated oxidative damage. Expression of CD163 is constitutive 
and is induced by stimulation of circulating monocytes and tissue macrophages. A soluble form 
of CD163 is released into plasma by proteolysis after oxidative stress37 or stimulation through 
toll-like receptors 2, 4 and 5.38 The concentration of plasma soluble CD163 is elevated in 
oxidative conditions such as diabetes,39 rheumatoid arthritis,40 and systemic sclerosis.41 
Accordingly, our results suggest that higher oxidative stress may predispose toward the 
development of de novo-onset cGVHD. 
Biomarker proteins associated with chronic GVHD have been examined in several 
studies.12-14, 42-48 Most studies selected candidate proteins based on presumed immunological 
pathways or on results of studies investigating acute GVHD. One recent study identified 5 
diagnostic proteins that distinguished refractory chronic GVHD patients at disease onset from 
those who never had GVHD. The chemokine (C-X-C motif) ligand 9 (CXCL9) was most useful 
for diagnosing chronic GVHD.12 Another recent study validated a 4-protein diagnostic biomarker 
panel (CXCL9, ST2 [serum stimulation-2, IL1RL1 gene product], matrix metalloproteinase 3 and 
osteopontin) for diagnosis and severity of chronic GVHD.13 No studies have examined 
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prognostic plasma biomarker proteins associated with onset of chronic GVHD by mass 
spectrometry. 
Several studies have examined prognostic biomarker proteins associated with the 
subsequent onset of cGVHD based on biological interest. BAFF concentrations ≥10 ng/mL at 6 
months after HCT were associated with subsequent onset of cGVHD.14 Higher concentrations of 
TNF-α at 3-6 months or 2-4 weeks were associated with an increased risk of cGVHD.45, 46 
Higher concentrations of IL-10 at 4 months were associated with an increased risk of cGVHD.45 
Higher concentrations of IFN-γ at 3 months, TGF-β at 2-4 weeks and IL-15 at day 7 were 
associated with decreased risk of cGVHD.45, 46, 48 None of these proteins surfaced as a 
candidate in our mass spectrometry analysis. This result could be explained by several 
possibilities: (1) different sampling time points, (2) protein abundance that was too low for mass 
spectrometry analysis, (3) different diagnostic criteria for cGVHD, especially considering that 
previous studies could have included patients with late acute GVHD, (4) different time intervals 
between sample collection and onset of cGVHD, and (5) differences in immunosuppressive 
treatment at the time of sample collection, since none of the prior studies considered prednisone 
doses at sample collection. 
This study has several limitations. First, the study was not designed to characterize the 
positive-predictive value of testing CD163 concentrations as a prognostic biomarker for de
novo-onset cGVHD. This question remains to be tested in future studies. Second, further 
verification of the association of CD163 concentrations with de novo-onset cGVHD is needed, 
because the current study did not account for multiple comparisons. Third, because we limited 
the study to patients who were on minimal doses of corticosteroids, the predictive value for 
patients receiving corticosteroids remains to be determined. Lastly, proteins without suitable 
ELISA could not be tested, and await technology advances in the future. 
We have learned that the 2014 NIH consensus for biomarker development was very helpful 
for designing the study and for reporting the results in a standardized way.49 This study 
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illustrates challenges but also the progress in design and rigor of standardization in conducting 
studies of biomarker development in cGVHD. Identification of prognostic biomarkers is crucial 
for early intervention, but it might be more challenging than identification of diagnostic 
biomarkers, since patients do not yet have the event at sample collection and the signals 
associated with the later event of interest may be subtle. 
The careful design of the cohort represents a strength of our study. Since all patients had 
quiescent GVHD activity under minimum glucocorticoid administration at day 80, the 
interpretation of the results is not confounded by the possible effects of glucocorticoid 
administration. Although the effect of glucocorticoid administration on CD163 concentrations 
remains to be tested in future studies, our results suggest that that monocyte/macrophage 
activation or increased oxidative stress contributes to the pathogenesis of de novo-onset 
cGVHD.  
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Figure 1. Cumulative incidence rates of de novo-onset chronic GVHD according to 
concentrations of 4 plasma proteins at day 80 in the verification cohort. Thresholds were 
derived from the median concentration in the discovery cohort.
Figure 2. Plasma CD163 concentrations. Samples among 81 patients without prior acute 
GVHD were collected at day 80, and 31 developed no chronic GVHD and 50 developed de
novo-onset chronic GVHD. Samples of active chronic GVHD were collected at any time. Values 
are represented by dot blots with the mean ± standard error of mean. P values are derived from 
Wilcoxon two-sample tests. 
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